These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18667743)

  • 1. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.
    Rehman T; Fought J; Solomon R
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1610-4. PubMed ID: 18667743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C.
    Alioglu E; Saygi S; Turk U; Kirilmaz B; Tuzun N; Duman C; Tengiz I; Yildiz S; Ercan E
    Cardiovasc Ther; 2013 Jun; 31(3):168-73. PubMed ID: 22212518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M; Sauter M; Argirov M; Wörnle M
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
    Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
    Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease.
    Mainra R; Gallo K; Moist L
    Nephrology (Carlton); 2007 Oct; 12(5):510-3. PubMed ID: 17803476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
    Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
    Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Acetylcysteine does not artifactually lower plasma creatinine concentration.
    Haase M; Haase-Fielitz A; Ratnaike S; Reade MC; Bagshaw SM; Morgera S; Dragun D; Bellomo R
    Nephrol Dial Transplant; 2008 May; 23(5):1581-7. PubMed ID: 18202091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
    Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
    J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive effect of N-acetylcysteine on contrast-induced nephropathy following coronary angiography and angioplasty.
    Kamiyama N; Ogawa R; Hamada H; Ohno T; Asano R; Umemura J; Yoshida H
    Yakugaku Zasshi; 2008 Sep; 128(9):1333-9. PubMed ID: 18758148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
    Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
    Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
    Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
    AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients.
    Wacker-Gußmann A; Bühren K; Schultheiss C; Braun SL; Page S; Saugel B; Schmid S; Mair S; Schoemig A; Schmid RM; Huber W
    AJR Am J Roentgenol; 2014 Feb; 202(2):452-8. PubMed ID: 24450691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.